AVANIR to Present at the BIOCOM Investor Conference

ALISO VIEJO, Calif.--(Business Wire)--
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced that the Company will
present at the BIOCOM Investor Conference on Monday, October 26th at 2:30 p.m.
Eastern time (11:30 a.m. Pacific time) at the Hyatt Regency in La Jolla. The
BIOCOM Investor Conference provides the opportunity for participating companies
to present to institutional and private equity investors. For more information
visit http://www.biocom.org/event/2009_Investor_Conference/.

A live audio webcast of the presentation will be available by visiting AVANIR's
website at www.avanir.com. To listen to the live presentation, please go to
AVANIR's website prior to the start of the presentation to register, download
and install the necessary software. An archive of the presentation at the BIOCOM
Investor Conference will be available on the Company's website for 30 days.

About AVANIR

AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on
acquiring, developing, and commercializing novel therapeutic products for the
treatment of central nervous system disorders. AVANIR's lead product candidate,
Zenvia, is being developed for the treatment of pseudobulbar affect (PBA) and
has successfully completed a Phase III trial for diabetic peripheral neuropathic
(DPN) pain. AVANIR has licensed its MIF inhibitor program to Novartis
International Pharmaceuticals Ltd. and has sold its anthrax monoclonal antibody
program to Emergent BioSolutions. The Company's first commercialized product,
Abreva® (docosanol), is marketed in North America by GlaxoSmithKline Consumer
Healthcare and is the leading over-the-counter product for the treatment of cold
sores. Further information about AVANIR can be found at www.avanir.com and
further information about pseudobulbar affect can be found at www.PBAinfo.org.

To be included on AVANIR's e-mail alert list, click on the link below or visit
AVANIR's website: http://www.b2i.us/irpass.asp?BzID=958&to=ea&s=0.

AVANIR Investor Contacts
Eric Benevich
Brenna Mullen
949-389-6700
ir@avanir.com

Copyright Business Wire 2009